| Antigens |
Clones |
Specificity |
Dilution |
Sources |
|
| CD2 |
12–15 |
Cell adhesion molecule |
10–20 µg/ml |
Southern Biotechnology Associates, Inc |
| CD3 |
7D6 |
T cells |
20–30 µg/ml |
Coulie and colleagues14 |
| CD4 |
RM4–5 |
T helper cells |
20 µg/ml |
Pharmingen |
| CD8 |
53–6.7 |
T cells |
20 µg/ml |
Pharmingen |
| CD90/Thy 1.2 |
53–2.1 |
T cells |
10–20 µg/ml |
Pharmingen |
TCR ß
|
H57–597 |
T cells (TCR) |
20–30 µg/ml |
Pharmingen |
TCR  |
13D5 |
T cells (TCR) |
20–30 µg/ml |
Peterman and colleagues15 |
| TCR Vß8 |
F23.2 |
T cells (TCR) |
20 µg/ml |
ATCC |
| TCR Vß6 |
44.22.1 |
T cells (TCR) |
20 µg/ml |
Payne and colleagues16 |
| B220/CD45R |
RA3–6B2 |
B cells |
5–10 µg/ml |
Pharmingen |
| IgD |
LoMD6 |
B cells |
5–10 µg/ml |
Lefebvre and colleagues17 |
| IgM |
LoMM9 |
B cells |
5–10 µg/ml |
Lefebvre and colleagues17 |
| MHC-II |
14.4.4 |
B cells, DC, M |
5–10 µg/ml |
ATCC |
| CD11c |
N418 |
Mainly DC |
5–10 µg/ml |
Metlay and colleagues18 |
| CD11c |
HL3 |
Mainly DC |
5–10 µg/ml |
Pharmingen |
| CD11b/Mac-1 |
M1/70 |
M |
5–10 µg/ml |
Pharmingen |
| NK |
5E6 |
NK cells |
10–20 µg/ml |
Pharmingen |
| Pan-NK |
DX5 |
NK cells |
10–20 µg/ml |
Pharmingen |
| Ly-6G/GR1 |
RB6–8C5 |
Granulocytes |
10–20 µg/ml |
Pharmingen |
| PMN antigen |
7/4 |
Neutrophils |
10–20 µg/ml |
Caltag |
| CD40 |
3/23 |
B cells, DC, M |
10–20 µg/ml |
Hasbold and colleagues19 |
| Intracytoplasmic granules |
2A1 |
Mature DC |
5–10 µg/ml |
Inaba and colleagues20 |
| Intracytoplasmic granules |
M342 |
Mature DC |
Undiluted supernatant |
Agger and colleagues21 |
| DEC-205 |
NLDC-145 |
Mature DC |
20–30 µg/ml |
Kraal and colleagues22 |
| CD35 |
8C12 |
CR1 (Follicular DC) |
5–10 µg/ml |
Pharmingen |
| CD86/B7.2 |
GL1 |
Activated B cells, DC, M |
10–20 µg/ml |
Hathcock and colleagues23 |
| CD25 |
7D4 |
Activated T cells, B cells, DC |
10–20 µg/ml |
Pharmingen |
| Ly-77 |
GL7 |
Activated T cells, B cells |
10–20 µg/ml |
Pharmingen |
| CD44 |
1M7 |
Activated T cells |
10–20 µg/ml |
Pharmingen |
| CD69 |
H1.2F3 |
Activated T cells |
10–20 µg/ml |
Pharmingen |
| Phosphotyrosin |
4G10 |
Activated cells |
20–30µg/ml |
Upstate Biotechnology Incorporation |
| OX40 |
mOX40L–hIgG1* |
Activated T cells |
20–30µg/ml |
Cantab Pharmaceutical Research Ltd |
| VCAM-1 |
M/K-2 |
Adhesion molecule |
10–20 µg/ml |
R&D Systems |
| Anti-Ars Ig |
Ars-BSA° |
Ars specific B cells |
20 µg/ml |
|
| IL-2 |
S4B6 |
Cytokine |
20–30 µg/ml |
Pharmingen |
| IL-4 |
11B11 |
Cytokine |
20–30 µg/ml |
Pharmingen |
INF- |
Db1 |
Cytokine |
20–30 µg/ml |
Paineau and colleagues24 |
| IL-10 |
JESS-2A5 |
Cytokine |
20–30 µg/ml |
Pharmingen |
|
| *Fusion protein; °synthesised hapten carrier protein. |
Ars, arsenate; BSA, bovine serum albumin; DC, dendritic cell; h, human; IFN- , interferon ; Ig, immunoglobulin; IL, interleukin; L, ligand; MHC, major histocompatibility complex; M , macrophage; NK, natural killer; PMN, polymorphonuclear cell; TCR, T cell receptor; VCAM, vascular cell adhesion molecule.
|